<DOC>
	<DOCNO>NCT01993329</DOCNO>
	<brief_summary>This randomise , double blind , double-dummy , placebo-controlled , three way crossover , single centre study subject asthma undergoing inhalation methacholine ATP ass PC20 response two dose level AF-219 compare placebo .</brief_summary>
	<brief_title>A Study Evaluate Effect AF-219 Methacholine Hyper-reactivity Subjects With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Methacholine Chloride</mesh_term>
	<criteria>Nonsmokers former smoker , stop smoke 6 month prior screen . Former smoker smoke history 5 pack year ( 1 pack 20 cigarette per day 5 year ) . Prebronchodilator ( abstain Short act β2agonist ≥8 hr ) Forced Expiratory Volume ( FEV1 ) ≥70 % predict normal value screen visit . Prebronchodilator ( abstain Short act β2agonist ≥8 hr ) Forced Expiratory Volume ( FEV1 ) ≥70 % predict normal value OR le 70 % must within +/ 12 % screening FEV1 prior randomization . History diagnosis asthma least 6 month prior screen accord Global Initiative Asthma guideline ( GINA , 2012 ) . Use Short act β2agonist therapy ( ≤ 8 puff per day ) least 4 week prior screen prior randomisation . Positive response methacholine challenge ( PC20 ≤ 8 mg/mL ) screening . Positive response ATP challenge ( PC20 ≤ 200 µmol/mL ) screening . Hospitalized attend emergency department asthma attack 12 month prior screen . Exacerbation asthma low respiratory tract infection 4 week screen . Upper respiratory tract infection 4 week screen prior randomization require treatment antibiotic . Inhaled systemic corticosteroid ( oral , intravenous , intramuscular ) within 4 week prior screen . Shortacting longacting antihistamine within 48hrs 7 day , respectively , prior screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>